External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

SUO 2024

We will be contributing to topics related to
-
11:00 PM
Duration 1hr Dallas, USA / Virtual (Hybrid)
Disease-free survival and overall survival in patients with high-risk muscle-invasive bladder cancer who have persistent circulating tumor DNA-negative biomarker status post-cystectomy: IMvigor011 study surveillance analysis
E Goluboff, Y Shi, Z J Assaf, V Degaonkar, T. Powles; J. Bellmunt; J. Bjergaard Jensen; M. Gross-Goupil; S. Bracarda; J. Gschwend; A. Kann; L. Makaroff; H. Nishiyama; D. Castellano, S Jiang, J H Ku, S H Park, B M Gonzalez, M Maruzzo, D Yi, Y Urun, R M Barrera, C Buttigliero
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon